Bristol-Myers Squibb
Also known as: Adnexus, A Bristol-Myers Squibb R&D Company | Bristol-Mayers Squibb | Bristol-Meyers Squibb & Pfizer | BRISTOL MYERS | BRISTOL-MYERS | Bristol-Myers K.K. | Bristol-Myers Squibb | BRISTOL MYERS SQUIBB | BRISTOL-MYERS SQUIBB | Bristol-Myers-Squibb/Astra-Zeneca | Bristol-Myers Squibb (BMS) | Bristol Myers Squibb Co. and Ono Pharmaceutical Co., Ltd | Bristol-Myers Squibb Company | Bristol Myers Squibb Company (BMS) | Bristol-Myers Squibb, Korea | Bristol-Myers Squibb Research and Development | Bristol-Myers Suibb | Briston-Myers Squibb | Celegene/BMS | Celgene a wholly owned subsidiary of BMS | Celgene-BMS | Celgene Corporation, a Bristol-Myers Squibb Company | COMBE | Juno Therapeutics, Inc. a Bristol Myer-Squibb Company | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Medical Department, Bristol-Myers Squibb
Highest phase reached
Phase 4
First clinical trial
Jan 1, 1995First marketed drug
Feb 20, 1945First NDA
Sep 25, 1950Last known activity
May 18, 2026
Timeline
1850s
- Jan 1, 1858
Bristol-Myers Squibb— Founded
1980s
- Jan 1, 1989
Bristol-Myers— Acquired
- Jan 1, 1989
Squibb— Acquired
- Apr 14, 1989
naltrexone— Marketing Organization
1990s
- Jan 1, 1994
2000s
- Jan 1, 2001
DuPont— Acquired
- Dec 23, 2005
abatacept— NDA Organization
- Jan 1, 2007
Adnexus— Acquired
- Jan 1, 2008
Kosan Biosciences— Acquired
- Jan 1, 2009
Medarex— Acquired
2010s
- Jan 1, 2010
ZymoGenetics— Acquired
- Jan 1, 2011
Amira Pharmaceuticals— Acquired
- Jan 1, 2012
Amylin— Acquired
- Jan 1, 2012
Inhibitex— Acquired
- Jan 1, 2014
Galecto Biotech— Acquired
- Jan 1, 2014
iPierian— Acquired
- Jan 1, 2015
Cardioxyl Pharmaceuticals— Acquired
- Jan 1, 2015
Flexus Biosciences— Acquired
- Jan 3, 2019
Celgene— Acquired
2020s
- Oct 5, 2020
MyoKardia, Inc.— Acquired
- Jun 7, 2022
Turning Point Therapeutics— Acquired
- Apr 21, 2023
epinephrine— NDA Secondary Org
- Oct 9, 2023
Mirati Therapeutics Inc.— Acquired
- Dec 6, 2023
RayzeBio, Inc.— Acquired
- Dec 22, 2023
Karuna Pharmaceuticals— Acquired
- Mar 11, 2025
Abecma— Acquired
Drugs by trial phase (932 distinct, 3797 trials)
Phase 4 (46 own, 58 via acquisition)
Phase 3 (70 own, 111 via acquisition)
Phase 2 (205 own, 155 via acquisition)
Phase 1 (162 own, 90 via acquisition)
Indications
Approved for
- Arthritis, Juvenile
- Arthritis, Rheumatoid
- Atrial Fibrillation
- Breast Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Coronary Disease
- Depression
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Dyslipidemias
- Embolism and Thrombosis
- Febrile Neutropenia
- Gastrointestinal Stromal Tumors
- Hepatitis B
- Hepatitis B, Chronic
- Hepatitis C, Chronic
- HIV Infections
- Hypercholesterolemia
- Hyperlipoproteinemia Type III
- Hypertension
- Infections
- Intraabdominal Infections
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Melanoma
- Multiple Myeloma
- Neoplasms
- Osteomyelitis
- Otitis Media
- Ovarian Neoplasms
- Pharyngitis
- Pneumonia
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Pulmonary Embolism
- Scalp Dermatoses
- Sinusitis
- Skin Diseases, Bacterial
- Skin Diseases, Infectious
- Small Cell Lung Carcinoma
- Stroke
- Testicular Neoplasms
- Tonsillitis
- Urinary Tract Infections
- Venous Thrombosis
Studied for
- Acquired Immunodeficiency Syndrome
- Acute Coronary Syndrome
- Adenocarcinoma
- Adenocarcinoma, Bronchiolo-Alveolar
- Adenocarcinoma, Clear Cell
- Adenocarcinoma of Lung
- Adenomyoepithelioma
- Adrenocortical Carcinoma
- Aggression
- AIDS Dementia Complex
- AIDS-Related Complex
- Albuminuria
- Alcoholism
- Alopecia
- Alopecia Areata
- Alzheimer Disease
- Amyloidosis
- Anemia, Sickle Cell
- Anorexia
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Antiphospholipid Syndrome
- Anxiety Disorders
- Aortic Valve Stenosis
- Arterial Occlusive Diseases
- Arteritis
- Arthralgia
- Arthritis
- Arthritis, Juvenile
- Arthritis, Psoriatic
- Arthritis, Rheumatoid
- Asperger Syndrome
- Asthma
- Astrocytoma
- Atherosclerosis
- Atrial Fibrillation
- Atrial Flutter
- Atrial Remodeling
- Attention Deficit Disorder with Hyperactivity
- Autism Spectrum Disorder
- Autistic Disorder
- Autoimmune Diseases
- Bacteremia
- Basal Cell Carcinoma
- Behavioral Symptoms
- Biliary Tract Neoplasms
- Bipolar Disorder
- Blast Crisis
- Blood Platelet Disorders
- Body Weight
- Body Weight Changes
- Bone Marrow Diseases
- Bone Neoplasms
- Brain Diseases
- Brain Infarction
- Brain Neoplasms
- Breast Neoplasms
- Burkitt Lymphoma
- Cachexia
- Candidiasis
- Candidiasis, Oral
- Carcinoid Tumor
- Carcinoma
- Carcinoma, Adenosquamous
- Carcinoma, Endometrioid
- Carcinoma, Hepatocellular
- Carcinoma, Large Cell
- Carcinoma, Medullary
- Carcinoma, Merkel Cell
- Carcinoma, Neuroendocrine
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Renal Cell
- Carcinoma, Small Cell
- Carcinoma, Squamous Cell
- Carcinoma, Transitional Cell
- Carcinosarcoma
- Cardiovascular Diseases
- Central Nervous System Diseases
- Central Nervous System Neoplasms
- Cerebral Infarction
- Chickenpox
- Child Development Disorders, Pervasive
- Cholangiocarcinoma
- Chondrosarcoma
- Chordoma
- Chronic Disease
- Coinfection
- Colitis
- Colitis, Ulcerative
- Colonic Neoplasms
- Colorectal Neoplasms
- Communicable Diseases
- Conduct Disorder
- Congenital Abnormalities
- Constriction, Pathologic
- Coronary Artery Disease
- Coronary Disease
- Coronary Restenosis
- Coronary Stenosis
- Crohn Disease
Marketed drugs (188)
Subsidiaries (22 direct, 55 total across the full acquisition tree)
- Abecma
- Adnexus
- Amira Pharmaceuticals
- Amylin
- Bristol-Myers
- Cardioxyl Pharmaceuticals
- Celgene
- DuPont
- Flexus Biosciences
- Galecto Biotech
- Inhibitex
- iPierian
- Karuna Pharmaceuticals
- Kosan Biosciences
- Medarex
- Mirati Therapeutics Inc.
- MyoKardia, Inc.
- RayzeBio, Inc.
- Squibb
- Turning Point Therapeutics
- Union Pharmacologique Scientifique Appliquee
- ZymoGenetics
- Ability Biomedical L2
- Abraxis L2
- Acetylon Pharmaceuticals Incorporated L2
- Algos Pharmaceutical Corp L2
- Anthrogenesis L2
- Avila Therapeutics L2
- Cheplin Laboratories L2
- Danisco L2
- Delinia, Inc. L2
- DuPont Merck L2
- EngMab AG L2
- Genencor L2
- Genpharm L2
- Gloucester Pharmaceuticals L2
- Houston Biotechnology L2
- Impact Biomedicines L2
- Juno Therapeutics, Inc. L2
- Mead Johnson L2
- MethylGene Inc. L2
- New England Nuclear L2
- PharmAkea, Inc. L2
- Pharmion L2
- Quanticel Pharmaceuticals L2
- Receptos L2
- Signal Pharmaceuticals L2
- Solae, LLC L2
- VentiRx Pharmaceuticals Inc. L2
- AbVitro L3
- American Bioscience L3
- American Pharmaceutical Partners L3
- Redox Therapies L3
- Stage Cell Therapeutics L3
- X-Body L3
Recent trials (50)
- NCT04400591Study directorN/A—
- NCT05170659Lead sponsorN/A—
- NCT05170659OfficialN/A—
- NCT05170672OfficialN/A—
- NCT05170672Lead sponsorN/A—
- NCT05170685OfficialN/A—
- NCT05170685Lead sponsorN/A—
- NCT05187286OfficialN/A—
- NCT05187286Lead sponsorN/A—
- NCT05926232Lead sponsorN/A—
- NCT05926232OfficialN/A—
- NCT06994117OfficialN/A—
- NCT06994117Lead sponsorN/A—
- NCT00575549CollaboratorN/A—
- NCT04771078OfficialN/A—
Details
- Founded
- Brooklyn, New York, US Jan 1, 1858
- First NDA
- Sep 25, 1950
- Last known activity
- May 18, 2026
Designations held
- Orphan drug
- Fast track
- Priority review
- Breakthrough therapy
- Accelerated approval